Saturday 17 October 2026
Export PLRZ’s income statement to Excel — free account
Polyrizon Ltd.
PLRZ Healthcare Biotechnology
10.00
0.01
−0.10%
Follow PLRZ
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 1,155.00 | 2.88 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 7,200.00 | 3,075.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 1 | 6 | 4 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (1) | (1) | (2) | (3) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (1) | (1) | (2) | (3) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (894.54) | (443.26) | (774.82) | (4.90) | |||||
| Cash flow | — | — | — | — | — | — | (1,257.78) | (383.57) | (573.50) | (6.65) | |||||
| Capex | — | — | — | — | — | — | (3.33) | 0.00 | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (1,261.11) | (383.57) | (573.50) | (6.67) | |||||
| Book value | — | — | — | — | — | — | (1,000.00) | (136.43) | 2,643.00 | 30.86 | |||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | (1) | (1) | (5) | ||||
| Capex | — | — | — | — | — | — | 0 | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (1) | (1) | (1) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | 0 | 2 | 12 | ||||
| Total debt | — | — | — | — | — | — | — | 0 | — | — | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (3) | (12) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | 0 | 5 | 21 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (108.60) | (50.61) | (24.72) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (29.79) | (45.79) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 109.99 | (60.65) | (25.38) | |||||
Negative figures in brackets.
Fundamentals updated 30 Sep 2026
Charts ten years each
Polyrizon Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MCRB Seres Therapeutics, Inc. | $25.2M | — (loss-making) | — (loss-making) | +96.79% (above 0%: growing) | n/m | −66.15% (below 0%: shrinking) | 100.00% | (2,890.35%) | Compare |
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRZ Polyrizon Ltd. | $23.7M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | |
| IMMP Prima BioMed Ltd | $23.7M | — (loss-making) | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.4M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $23.3M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| CNTX Context Therapeutics Inc. | $22.1M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $23.7M | — | — | +7,343.49% | — | −38.65% | 100.00% | 0.00% |
Polyrizon Ltd. (PLRZ) key facts
- Polyrizon Ltd. (PLRZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PLRZ traded at $10.00, a market capitalization of $23.7 million.
- Return on equity was −25.4% and debt-to-equity 0.00.